Novartis AG v Adarsh Pharma (2004)
High Court of Madras
Latest update: . Case: Indian Network for People living with HIV/AIDS v Union of India. Doctrine: Appeals in Compulsory Licensing.
High Court of Madras·P.D. Dinakaran & S.R. Singharavelu JJ·Division Bench·Decided 20 December 2004·2005 (1) CTC 27
Declining to decide the validity of the Exclusive Marketing Rights in an interim appeal, the Division Bench confirmed Novartis's imatinib injunction on an undertaking of free supply to patients.
Intas Laboratories Pvt Ltd v Novartis AG, Ali on Patents, www.aop.onl/intas-novartis
“These appeals are directed against the common order dated 28.4.2004” in which “the learned single Judge made absolute the order of ex parte injunction dated 20.01.2004 made in O.A.Nos. 13 to 17 of 2004 in C.S.No. 5 to 9 of 2004 in favour of the respondents/plaintiffs in each of the suits and dismissed the applications filed by the appellants/defendants to vacate the ex parte order of injunction dated 20.1.2004 in each of the suits.” (para 1) The plaintiffs sought to restrain the defendants from dealing in an “and cancer drug composed of ‘Beta-Crystalline form of Imatinib Mesylate’” “so long as the Exclusive Marketing Right granted by the Controller of Patents on 10.11.2003 under EMR” (“Exclusive Marketing Rights”) “No. 002 and notified in the Official Gazette on 13.12.2003 is subsisting” (para 2). Their case was that “by way of an interim measure, till the product patent application is taken up for consideration, provision is made in the Patents Act for granting Exclusive Marketing Rights (hereinafter referred to as ‘EMR’)” (para 3.1). “The main contention of the appellants/defendants is that the EMR obtained by the respondents/plaintiffs in each of the suits is not in accordance with the provisions of the Patents Act, 1970, as the conditions imposed under Section 24-B of the Patents Act, 1970 have not been satisfied” (para 9).
The Bench held that “it would not be proper for us to decide the said issue in appeals arising out of interim orders as the same would render the suit itself infructuous leaving nothing for the trial” (para 11), and that, the Single Judge having found the balance of convenience in the plaintiffs’ favour, “we find it difficult to interfere with the same.” (para 12.1) It held that “the public interest should not be made to suffer on account of legal battle between the trading parties, particularly in the case of supply of medicines for Chronic Myeloid Leukaemia.” (para 12.2) “Recording the undertaking of the learned Senior Counsel made on behalf of the respondents/plaintiffs, we confirm the order of interim injunction dated 28.4.2004 of the learned Single Judge” (para 14), on terms including that “the respondents/plaintiffs would supply Beta-Crystalline form of Imatinib Mesylate freely to all the patients, who are suffering from Chronic Myeloid Leukaemia and are earning less than Rs. 3,36,000 per month” (para 14(i)), and “all the original side appeals are disposed of accordingly. No costs.” (para 14(ix))
The Bench held that “it would not be proper for us to decide the said issue in appeals arising out of interim orders” and that the validity of the EMR (“Exclusive Marketing Rights”) “has to be tested only in the trial in the suits” (paras 11, 12.1).
Case page · Page updated 19 November 2026
www.aop.onl/intas-novartis